NEWPORT BEACH, Calif. / Aug 29, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in two investment conferences in September.
Event: H.C. Wainwright 25th Annual Global Investment Conference
Date: Tuesday, September 12, 2023
Time: 11:00 – 11:30 am ET
Event: Cantor 2023 Global Healthcare Conference
Date: Tuesday, September 26, 2023
Time: 9:10 – 9:40 am ET
Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com. Replays of the webcasts will be available for 90 days after the date of each presentation.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva®. The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or Facebook.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
| Last Trade: | US$9.73 |
| Daily Change: | 0.47 5.08 |
| Daily Volume: | 273,386 |
| Market Cap: | US$627.390M |
July 09, 2025 May 07, 2025 April 16, 2025 March 04, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
